CHAPTER 1 INTRODUCTION

1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1 Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTERS FIVE FORCES ANALYSIS

3.4.1. Bargaining Power of Buyers
3.4.2. Bargaining Power of Suppliers
3.4.3. Threat of Substitution
3.4.4. Threat of New Entrants
3.4.5. Competitive Rivalry

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in prevalence of infectious diseaseas and various types of cancer
3.5.1.2. Increase in awareness and acceptance of personalized medicines
3.5.1.3. Growth in biomarker identification market
3.5.1.4. Advancement in molecular diagnostics

3.5.2. Restrains

3.5.2.1. Stringent regulatory requirements for product approvals

3.5.3. Opportunity

3.5.3.1. High potential and increasing adoption of molecular diagnostics in emerging nations

CHAPTER 4 MOLECULAR DIAGNOSTICS MARKET, BY TYPE

4.1. OVERVIEW
4.2. INSTRUMENTS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. REAGENTS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. SOFTWARE & SERVICES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

5.1. OVERVIEW
5.2. INFECTIOUS DISEASES

5.2.1. Market size and forecast

5.3. ONCOLOGY

5.3.1. Market size and forecast

5.4. GENETIC TESTING

5.4.1. Market size and forecast

5.5. BLOOD SCREENING

5.5.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

CHAPTER 6 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. OVERVIEW
6.2. POLYMERASE CHAIN REACTION (PCR)

6.2.1. Market size and forecast

6.3. HYBRIDIZATION

6.3.1. Market size and forecast

6.4. DNA SEQUENCING

6.4.1. Market size and forecast

6.5. MICROARRAY

6.5.1. Market size and forecast

6.6. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

6.6.1. Market size and forecast

6.7. OTHERS

6.7.1. Market size and forecast

CHAPTER 7 MOLECULAR DIAGNOSTICS MARKET, BY END USER

7.1. OVERVIEW
7.2. HOSPITALS

7.2.1. Market size and forecast

7.3. LABORATORIES

7.3.1. Market size and forecast

7.4. OTHERS

7.4.1. Market size and forecast

CHAPTER 8 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.4. U.S.: market size and forecast
8.2.5. Canada: market size and forecast
8.2.6. Mexico: market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.4. Germany: market size and forecast
8.3.5. France market size and forecast
8.3.6. UK: market size and forecast
8.3.7. Italy: market size and forecast
8.3.8. Spain: market size and forecast
8.3.9. Rest of Europe: market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.4. Japan: market size and forecast
8.4.5. China market size and forecast
8.4.6. India: market size and forecast
8.4.7. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.4. Latin America: market size and forecast
8.5.5. Middle East market size and forecast
8.5.6. Africa: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. ABBOTT LABORATORIES, INC.

9.1.1. Overview
9.1.2. Operating business segments
9.1.3. Business performance
9.1.4. Key strategic moves & developments

9.2. BIOMRIEUX SA

9.2.1. Overview
9.2.2. Operating business segments
9.2.3. Business performance
9.2.4. Key strategic moves & developments

9.3. BECTON, DICKINSON AND COMPANY

9.3.1. Overview
9.3.2. Operating business segments
9.3.3. Business performance
9.3.4. Key strategic moves & developments

9.4. DANAHER CORP.

9.4.1. Overview
9.4.2. Operating business segments
9.4.3. Business performance
9.4.4. Key strategic moves & developments

9.5. GRIFOLS

9.5.1. Overview
9.5.2. Operating business segments
9.5.3. Business performance
9.5.4. Key strategic moves & developments

9.6. HOLOGIC INC.

9.6.1. Overview
9.6.2. Operating business segments
9.6.3. Business performance
9.6.4. Key strategic moves & developments

9.7. NOVARTIS AG

9.7.1. Overview
9.7.2. Operating business segments
9.7.3. Business performance
9.7.4. Key strategic moves & developments

9.8. ROCHE DIAGNOSTICS

9.8.1. Overview
9.8.2. Operating business segments
9.8.3. Business performance
9.8.4. Key strategic moves & developments

9.9. SIEMENS HEALTHCARE

9.9.1. Overview
9.9.2. Operating business segments
9.9.3. Business performance
9.9.4. Key strategic moves & developments

9.10. QIAGEN N.V.

9.10.1. Overview
9.10.2. Operating business segments
9.10.3. Business performance
9.10.4. Key strategic moves & developments